A Phase 4 interventional study of Omega-3 fatty acids and Placebo in Ultra High Risk for Psychosis, sponsored by Rene Kahn. Completed at 14 sites in 9 countries. Open to participants aged 13 Years to 20 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Rene Kahn · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Psychotic Disorders with a site in Spain — 15 open to participants now, 19 under way, 4 of them phase 3. Psychotic Disorders · Spain.
Among the 65 studies in Psychotic Disorders with a site in Spain, this one is the 26th largest by enrollment of the 49 interventional ones that give a count, is one of 5 that started in 2016, is one of 11 in phase 4, and was the 20th registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →15 of the 65 studies in Psychotic Disorders with a site in Spain are open now. Recruiting first, the newest first:
University of Oxford · Sites in Spain, Austria, Germany and 6 more countries
Ages 16–40
Fundació Sant Joan de Déu · Sites in Spain
Ages 18–65
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in Spain, United States, Argentina and 22 more countries
Ages 55–90
Fundació Sant Joan de Déu · Sites in Spain
Ages 18–40
Intra-Cellular Therapies, Inc. · Sites in Spain, United States, Bulgaria and 7 more countries
Ages 55+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 13 Years to 20 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 9 · Phase 4 11
First in 2004; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 146 is above the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Median enrollment 160 across the 49 interventional studies, 200 across the 15 observational. Of the 29 that completed or were terminated, 8 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 65 have an industry lead sponsor. The 10 most frequent:
Rene Kahn is the lead sponsor of 3 studies on the registry; none are open to participants now.
Rene Kahn has 2 studies filed under Psychotic Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Psychotic Disorders with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT05905003Brigham and Women's HospitalAMP SCZ® Observational Study: PREDICT-DPACC | 2027-04-30 |
| NCT07946523Fundació Sant Joan de DéuAndy's Mind: A Co-created Serious Game for People With Psychosis (PSICOGAME) | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies in Psychotic Disorders with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether omega-3 fatty acids are effective in the prevention of psychosis in individuals at ultra-high risk for psychosis.
PURPOSE is a randomized double-blind placebo-controlled study. Main objective is to assess the effectivity of omega-3 fatty acid treatment in the prevention of psychosis. The primary outcome measure is the rate of transition to psychosis as determined through CAARMS. Subjects in the age range of 13-20 years with a higher chance of developing psychosis, as determined by the CAARMS, are treated for 6 months with omega-3 fatty acids or placebo. This study in conducted at 14 sites in 9 countries.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be treated daily with 1.2 gram omega-3 polyunsaturated fatty acids (720 mg eicosapentaenoic acid (EPA) and 480 mg Docosahexaenoic acid(DHA)) for six months.
Drug: Omega-3 fatty acids
Subjects will be treated daily with placebo for six months. Placebo capsules will contain a 1:1 combination of coconut oil and medium chain triglycerides because these do not contain polyunsaturated fatty acids and have no impact on omega-3 fatty acid metabolism. Placebo capsules also contain the same amount of vitamin E as the omega-3 capsules and 1% fish oil to mimic flavour and taste.
Other: Placebo
Also known as: Fishoil
Transition Rate
To compare transition rates to psychosis during 24 months of individual follow-up between the omega-3 fatty acids arm and the placebo arm. Starting point is the first administration of medication at the end of visit 2. Endpoint is the moment that a UHR subject makes a transition to psychosis according to the CAARMS criteria, which can be anytime between baseline and the 2 year post-baseline measurement (or no transition occurs, as only part of the sample is expected to transition).
Time frame: measured starting from baseline up to 2 years post-baseline
Discontinuation Rate
how many participants dropped out from the 2-year study, measurement starting at randomisation (baseline)
Time frame: measurement starting at baseline up to 2 years post-baseline
Symptomatology
change in PANSS total score between baseline and individual follow up after 2 years. The PANSS has a range in total score of min 30 until max 210, with higher values representing more severe symptoms.
Time frame: baseline to 2 years post-baseline
Psychosocial Functioning
Change in Social and Occupational Functioning Assessment Scale (SOFAS), from baseline to the 2-year timepoint. Min score is 0, max score is 100; higher scores reflects better functioning.
Time frame: measurement started at baseline up to the 2 year timepoint
Intelligence
This is incorrectly added as outcome measure, as IQ does not tend to change over a 2-year period. Here only the assessment at screening is presented. IQ is determined by the WAIS at, with a minimum score of 40, a maximum score of 160. Higher scores represent better cognitive functioning
Time frame: One time assessment of IQ
Blood Levels of Bioactive Lipids
Assessment of the 2 components of omega-3 fatty acids (EPA and DHA), change from baseline to 6 months. The 6 month timepoint was selected as the omega-3 fatty acids / placebo treatment ended at that timepoint, even though the primary endpoint (transition to psychosis) ran until 2 years post-baseline.
Time frame: measurement started at baseline up until 6 months
Positive and Negative Symptoms
Change in symptomatology will be examined with the Positive and Negative Syndrome Scale (PANSS) as the difference between the assessment at baseline and after 2 years post-baseline, with a score range between min 30 and max 210. Higher scores represent more severe symptoms.
Time frame: from baseline to 2 years post-baseline
Level of Functioning
Change in symptomatology will be examined with the Global Assessment of Functioning scale (GAF), from baseline to 2 years post-baseline. Total score ranges from 0 to 100, with higher numbers meaning better functioning.
Time frame: from baseline to 2 years post-baseline
Level of Depression
Change in symptomatology will be examined with the Beck's Depression Inventory (BDI), starting at baseline up until follow up after 2 years. Total score ranges from 0 to 63, with higher scores reflecting more severe symptoms.
Time frame: measured starting at baseline up to 2 years post-baseline
Role Functioning
Change in functioning, determined by the Global Functioning Role (GF:R) scale at baseline and follow up up until 2 years. This is a clinician-rated scale from 1 to 10 that measures a person's performance in school or work based on age, independence, and support needs. A score of 10 indicates superior functioning, while a score of 1 indicates extreme dysfunction.
Time frame: measurement started at baseline up until 2 years post-baseline
Social Functioning
Change in social functioning, determined by the Global Functioning Social (GF:S) scale at baseline and follow up until 2 years. This is a clinician-rated scale from 1 to 10, where higher numbers show better social skills and lower numbers show severe social isolation.
Time frame: measurement started at baseline up until 2 years post-baseline
Due to various difficulties, among which COVID, the goal of 220 randomized participants was not met.
| Milestone | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| Started | 71 | 75 |
| Completed | 56 | 57 |
| Not completed | 15 | 18 |
To compare transition rates to psychosis during 24 months of individual follow-up between the omega-3 fatty acids arm and the placebo arm. Starting point is the first administration of medication at the end of visit 2. Endpoint is the moment that a UHR subject makes a transition to psychosis according to the CAARMS criteria, which can be anytime between baseline and the 2 year post-baseline measurement (or no transition occurs, as only part of the sample is expected to transition).
| Participants | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| Transition to psychosis | 5 | 3 |
| Exceeding the maximally allowed dose of antipsychotics | 11 | 5 |
| Not meeting endpoint criteria | 51 | 60 |
how many participants dropped out from the 2-year study, measurement starting at randomisation (baseline)
| participants | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| Discontinuation Rate | 24 | 19 |
change in PANSS total score between baseline and individual follow up after 2 years. The PANSS has a range in total score of min 30 until max 210, with higher values representing more severe symptoms.
| score | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| Symptomatology | -0.234 (-0.316 to -0.152) | 0.0071 (0.0039 to 0.010) |
Change in Social and Occupational Functioning Assessment Scale (SOFAS), from baseline to the 2-year timepoint. Min score is 0, max score is 100; higher scores reflects better functioning.
| change in score | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| Psychosocial Functioning | 12.9 ± 9.0 | 13.7 ± 9.9 |
This is incorrectly added as outcome measure, as IQ does not tend to change over a 2-year period. Here only the assessment at screening is presented. IQ is determined by the WAIS at, with a minimum score of 40, a maximum score of 160. Higher scores represent better cognitive functioning
Results for this outcome have not been posted.
Assessment of the 2 components of omega-3 fatty acids (EPA and DHA), change from baseline to 6 months. The 6 month timepoint was selected as the omega-3 fatty acids / placebo treatment ended at that timepoint, even though the primary endpoint (transition to psychosis) ran until 2 years post-baseline.
| umol/mmol Hb | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| EPA | 3.4 ± 2.7 | 0.0 ± 0.6 |
| DHA | 5.8 ± 5.0 | -0.7 ± 3.5 |
Change in symptomatology will be examined with the Positive and Negative Syndrome Scale (PANSS) as the difference between the assessment at baseline and after 2 years post-baseline, with a score range between min 30 and max 210. Higher scores represent more severe symptoms.
| Total PANSS score | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| Positive and Negative Symptoms | -7.2 ± 19.0 | -13.7 ± 14.2 |
Change in symptomatology will be examined with the Global Assessment of Functioning scale (GAF), from baseline to 2 years post-baseline. Total score ranges from 0 to 100, with higher numbers meaning better functioning.
| GAF total score | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| Level of Functioning | 7 ± 1.4 | 7.2 ± 1.5 |
Change in symptomatology will be examined with the Beck's Depression Inventory (BDI), starting at baseline up until follow up after 2 years. Total score ranges from 0 to 63, with higher scores reflecting more severe symptoms.
| Total score | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| Level of Depression | -10.0 ± 6.4 | -11.9 ± 6.9 |
Change in functioning, determined by the Global Functioning Role (GF:R) scale at baseline and follow up up until 2 years. This is a clinician-rated scale from 1 to 10 that measures a person's performance in school or work based on age, independence, and support needs. A score of 10 indicates superior functioning, while a score of 1 indicates extreme dysfunction.
| GF Role total score | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| Role Functioning | 0.9 ± 1.4 | 0.9 ± 1.5 |
Change in social functioning, determined by the Global Functioning Social (GF:S) scale at baseline and follow up until 2 years. This is a clinician-rated scale from 1 to 10, where higher numbers show better social skills and lower numbers show severe social isolation.
| Total GF Social score | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| Social Functioning | 0.7 ± 1.4 | 1.0 ± 1.4 |
Collected over The period between randomization/baseline until 2 years post-baseline.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Omega-3 Fatty Acids | 0/67 (0%) | 15/67 (22.4%) | 22/67 (32.8%) |
| Placebo | 0/68 (0%) | 13/68 (19.1%) | 12/68 (17.6%) |
| Event | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| Exacerbation of depressive symptomsPsychiatric disorders | 3/67 | 1/68 |
| Suicidal ideationPsychiatric disorders | 3/67 | 3/68 |
| Suicide attemptPsychiatric disorders | 2/67 | 3/68 |
| PregnancyPregnancy, puerperium and perinatal conditions | 2/67 | 0/68 |
| AccidentInjury, poisoning and procedural complications | 1/67 | 0/68 |
| Exacerbation of anxiety symptomsPsychiatric disorders | 1/67 | 1/68 |
| Congenital heart defectCongenital, familial and genetic disorders | 1/67 | 0/68 |
| Penis fractureReproductive system and breast disorders | 1/67 | 0/68 |
| Biliary colicHepatobiliary disorders | 1/67 | 0/68 |
| SeptoplastySurgical and medical procedures | 1/67 | 0/68 |
| Event | Omega-3 Fatty Acids | Placebo |
|---|---|---|
| Nausea and VomitingGastrointestinal disorders | 9/67 | 3/68 |
| Common ColdInfections and infestations | 7/67 | 2/68 |
| Suicidal IdeationPsychiatric disorders | 6/67 | 7/68 |
Eleven participants were excluded from the analyses due to not meeting inclusion criteria at baseline
| Age, Continuous(years) | Omega-3 Fatty Acids | Placebo | Total |
|---|---|---|---|
| Mean | 16.3 ± 1.7 | 16.0 ± 1.8 | 16.1 ± 1.8 |
| Sex: Female, Male(Participants) | Omega-3 Fatty Acids | Placebo | Total |
|---|---|---|---|
| Female | 37 | 38 | 75 |
| Male | 30 | 30 | 60 |
| Race/Ethnicity, Customized(Participants) | Omega-3 Fatty Acids | Placebo | Total |
|---|---|---|---|
| Ethnicity — White | 58 | 58 | 116 |
| Ethnicity — Black | 2 | 0 | 2 |
| Ethnicity — East Asian | 2 | 0 | 2 |
| Ethnicity — Asian Indian | 1 | 0 | 1 |
| Ethnicity — Middle Eastern | 1 | 3 | 4 |
| Ethnicity — Other | 3 | 7 | 10 |
| Region of Enrollment(participants) | Omega-3 Fatty Acids | Placebo | Total |
|---|---|---|---|
| Austria | 19 | 19 | 38 |
| Netherlands | 12 | 13 | 25 |
| Norway | 1 | 0 | 1 |
| Italy | 10 | 10 | 20 |
| United Kingdom | 1 | 2 | 3 |
| Israel | 4 | 2 | 6 |
| Switzerland | 9 | 11 | 20 |
| Germany | 1 | 1 | 2 |
| Spain | 10 | 10 | 20 |
| IQ(units on a scale) | Omega-3 Fatty Acids | Placebo | Total |
|---|---|---|---|
| Mean | 98.1 ± 17.7 | 101.0 ± 18.5 | 99 ± 19 |
| Major Depressive Disorder (current)(Participants) | Omega-3 Fatty Acids | Placebo | Total |
|---|---|---|---|
| Count of participants | 36 | 32 | 68 |
| Substance abuse and/or dependence in past 12 months(Participants) | Omega-3 Fatty Acids | Placebo | Total |
|---|---|---|---|
| Count of participants | 4 | 5 | 9 |
| Positive And Negative Symptoms Scale total score(units on a scale) | Omega-3 Fatty Acids | Placebo | Total |
|---|---|---|---|
| Mean | 59.0 ± 13.8 | 60.2 ± 15.1 | 59.6 ± 14.3 |
8 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Feb 2023, 76 months.
Results were first posted in Nov 2026, 3 years 9 months after primary completion.
Of 45 non-industry phase 4 interventional studies under Psychotic Disorders, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 71. This study's 76 months is above that.
Counting every sponsor, half of 51 studies reached it within 58 months; a quarter within 32 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omega-3 fatty acid